Online citations, reference lists, and bibliographies.

Production Of A Novel N‐terminal PEGylated Crisantaspase

Karin Torres-Obreque, Giovanna Pastore Meneguetti, D. Custodio, G. Monteiro, A. Pessoa-Júnior, C. Rangel-Yagui
Published 2018 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Crisantaspase is an asparaginase enzyme produced by Erwinia chrysanthemi and used to treat acute lymphoblastic leukemia (ALL) in case of hypersensitivity to Escherichia coli l‐asparaginase (ASNase). The main disadvantages of crisantaspase are the short half‐life (10 H) and immunogenicity. In this sense, its PEGylated form (PEG‐crisantaspase) could not only reduce immunogenicity but also improve plasma half‐life. In this work, we developed a process to obtain a site‐specific N‐terminal PEGylated crisantaspase (PEG‐crisantaspase). Crisantaspase was recombinantly expressed in E. coli BL21(DE3) strain cultivated in a shaker and in a 2‐L bioreactor. Volumetric productivity in bioreactor increased 37% compared to shaker conditions (460 and 335 U L−1 H−1, respectively). Crisantaspase was extracted by osmotic shock and purified by cation exchange chromatography, presenting specific activity of 694 U mg−1, 21.7 purification fold, and yield of 69%. Purified crisantaspase was PEGylated with 10 kDa methoxy polyethylene glycol‐N‐hydroxysuccinimidyl (mPEG‐NHS) at different pH values (6.5–9.0). The highest N‐terminal pegylation yield (50%) was at pH 7.5 with the lowest poly‐PEGylation ratio (7%). PEG‐crisantaspase was purified by size exclusion chromatography and presented a KM value three times higher than crisantaspase (150 and 48.5 µM, respectively). Nonetheless, PEG‐crisantaspase was found to be more stable at high temperatures and over longer periods of time. In 2 weeks, crisantaspase lost 93% of its specific activity, whereas PEG‐crisantaspase was stable for 20 days. Therefore, the novel PEG‐crisantaspase enzyme represents a promising biobetter alternative for the treatment of ALL.
This paper references
Spectrila: Summary of product characteristics
(2017)
10.1248/BPB.B13-00661
Discussion about several potential drawbacks of PEGylated therapeutic proteins.
F. Zhang (2014)
Pegylated L-asparaginase. European Patent, International publication number: WO 2011/003886 (13.01.2011 Gazette 2011/02)
T. Abribat (2012)
Pegylated l- asparaginase
ティエリ アブリバト (2010)
10.1007/s10637-014-0102-9
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase
Wei-Wen Chien (2014)
10.1016/j.bbapap.2014.03.013
Improvement of stability and enzymatic activity by site-directed mutagenesis of E. coli asparaginase II.
Shikha Verma (2014)
10.1002/jps.24217
Noncovalent PEGylation of L-asparaginase using PEGylated polyelectrolyte.
Takaaki Kurinomaru (2015)
10.1002/bab.1215
Comparison of modification of a bacterial uricase with N‐hydroxysuccinimide esters of succinate and carbonate of monomethoxyl poly(ethylene glycol)
Chun Zhang (2014)
10.1038/nmeth.2089
NIH Image to ImageJ: 25 years of image analysis
C. Schneider (2012)
10.1038/nprot.2006.346
PEGylation of native disulfide bonds in proteins
S. Brocchini (2006)
Scientific and Technological Development (CNPq-Brazil), and the Coordination of Improvement of Higher Education Personnel (CAPES, Brazil, process number: 001)
10.1002/ELPS.200600807
Native PAGE eliminates the problem of PEG–SDS interaction in SDS‐PAGE and provides an alternative to HPLC in characterization of protein PEGylation
Chunyang Zheng (2007)
10.1021/ja504390x
Therapeutic protein-polymer conjugates: advancing beyond PEGylation.
Emma M. Pelegri-O’Day (2014)
High Cell Density Fermentation of Escherichia coli Using the New BrunswickTM BioFlo R © 115
S. Willard (2014)
10.1093/nar/gki464
H++: a server for estimating pKas and adding missing hydrogens to macromolecules
J. C. Gordon (2005)
10.1074/jbc.M116.728485
Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity*
Hien Anh Nguyen (2016)
10.1016/j.ijpharm.2013.06.022
N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.
Ling Wu (2013)
10.1016/j.jconrel.2014.02.002
Process for protein PEGylation.
D. Pfister (2014)
High Cell Density Fermentation of Escherichia coli Using the New BrunswickTM BioFlo R
B. Li (2014)
Principles of microbe and cell cultivation
S. Pirt (1975)
10.1002/BIT.20327
Characterization of the metabolic burden on Escherichia coli DH1 cells imposed by the presence of a plasmid containing a gene therapy sequence.
A. Rozkov (2004)
10.1021/bp000163r
Structural and Functional Stabilization of L‐Asparaginase via Multisubunit Immobilization onto Highly Activated Supports
V. Balcão (2001)
10.1097/CCO.0b013e32835d7d85
Optimizing asparaginase therapy for acute lymphoblastic leukemia
C. Rizzari (2013)
10.1016/j.addr.2009.02.010
PEG conjugates in clinical development or use as anticancer agents: an overview.
G. Pasut (2009)
10.1016/j.jconrel.2011.10.037
State of the art in PEGylation: the great versatility achieved after forty years of research.
G. Pasut (2012)
10.1016/J.JBIOTEC.2006.07.037
L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization.
Georgia A. Kotzia (2007)
10.1023/A:1016042220817
Characterization and Stability of N-terminally PEGylated rhG-CSF
O. Kinstler (2004)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar